CoQ-Clear 100 Ubiquinol 60sg by NuMedica
CoQ-Clear 100 Ubiquinol is a dietary supplement formulated by NuMedica, an innovative supplement producer.* It uses CoQ1010, known as ubiquinol, an active form of COQ10. Some individuals may absorb it faster than ubiquinone.*
Who May Take CoQ-Clear 100 Ubiquinol 60sg by NuMedica?
You may take CoQ-Clear 100 Ubiquinol by NuMedica of you:
- want to improve their cellular energy production*
- suffered heart failure*
- have common headaches*
What May CoQ-Clear 100 Ubiquinol by NuMedica Support?
The potential effects of NuMedica CoQ-Clear 100 Ubiquinol include:
- enhanced cellular energy production*
- antioxidant protection*
- support for cardiovascular health*
- cancer prevention (for certain types of cancer)*
Supplements support your health but do not replace a balanced diet. Always check with your doctor if you have doubts about a new supplement. If you want to learn more, book a FREE product consultation to discuss this or other supplements Covenant Health Products provides.
Recommendation:
NuMedica suggests taking one softgel 1-2 times per day with a meal or as directed by your healthcare practitioner.
Serving size: 1 Softgel
Servings per container:60
Amount per serving:
Coenzyme Q10 (as ubiquinol) 100 mg
Other Ingredients: Citrus oil (GRAS certified; natural food grade), gelatin (bovine), glycerin, purified water, caprylic acid, capric acid, alpha-lipoic acid, caramel liquid (softgel color).
Does Not Contain: Milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soy, artificial colors, sweeteners or preservatives.
Kaneka QH™ is a trademark of Kaneka Nutrients L.P.
References:
- Ghasemloo, E., Mostafavi, H., Hosseini, M., Forouzandeh, M., Eskandari, M., & Mousavi, S. S. (2021). Neuroprotective effects of coenzyme Q10 in Parkinson's model via a novel Q10/miR-149-5p/MMPs pathway. Metabolic brain disease, 36(7), 2089–2100. https://doi.org/10.1007/s11011-021-00795-4
- Shidal, C., Yoon, H.-S., Zheng, W., Wu, J., Franke, A. A., Blot, W. J., Shu, X.-O., & Cai, Q. (2021). Prospective study of plasma levels of coenzyme Q10 and lung cancer risk in a low-income population in the Southeastern United States. Cancer Medicine, 10(4), 1501–1509. https://doi.org/10.1002/cam4.3637